相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests Either Too Narrow or Too Broad
Madison K. Kilbride et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer
Allison W. Kurian et al.
JAMA ONCOLOGY (2020)
Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women
Julie R. Palmer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
NCCN: Continuing Education
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients
Allison W. Kurian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk
Jennifer L. Caswell-Jin et al.
GENETICS IN MEDICINE (2018)
Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results
Angela R. Bradbury et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results
Angela R. Bradbury et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer
Allison W. Kurian et al.
JAMA ONCOLOGY (2018)
Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests
Madison K. Kilbride et al.
JAMA ONCOLOGY (2018)
Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing
Jacqueline Mersch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics
Sarah S. Kalia et al.
GENETICS IN MEDICINE (2017)
Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls
Jenna Lilyquist et al.
GYNECOLOGIC ONCOLOGY (2017)
NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017 Featured Updates to the NCCN Guidelines
Samir Gupta et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer
Fergus J. Couch et al.
JAMA ONCOLOGY (2017)
Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing
Angela R. Bradbury et al.
GENETICS IN MEDICINE (2016)
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2016)
Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer
Nadine Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Genetic Misdiagnoses and the Potential for Health Disparities
Arjun K. Manrai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
Treatment Decision Making and Genetic Testing for Breast Cancer Mainstreaming Mutations
Steven J. Katz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
Mark E. Robson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment
Andrea Desmond et al.
JAMA ONCOLOGY (2015)
Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing
Angela R. Bradbury et al.
GENETICS IN MEDICINE (2015)
ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome
OBSTETRICS AND GYNECOLOGY (2014)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer
Michael J. Hall et al.
CANCER (2009)
分享论文
